首页> 美国卫生研究院文献>Annals of Hepato-Biliary-Pancreatic Surgery >Pancreas club international joint symposium on pancreatic cancer 2012 Kyoto: down staging chemo±radiotherapy for borderline resectable pancreatic cancer
【2h】

Pancreas club international joint symposium on pancreatic cancer 2012 Kyoto: down staging chemo±radiotherapy for borderline resectable pancreatic cancer

机译:胰腺俱乐部国际胰腺癌联合研讨会2012年京都:分期进行化学±放疗以治疗可切除的交界性胰腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This manuscript summarized one section out of the international symposium, Pancreatic Cancer 2012, which was held last October 4th through 6th in Kyoto (Japan) under the theme, "We are the Team: Opening the Door to the Next Step for Pancreatic Cancer Therapy." Borderline resectable pancreatic cancer (BRPC) is a specific clinical presentation with features in between those of resectable and locally advanced pancreatic cancers. The classification of pancreatic cancer is an important issue given that a cancer may look resectable but be high-risk for R1 or R2 resection. Considering that margin-negative resection is a fundamental requirement for curing pancreatic cancer, this issue is one of the most interesting to pancreatic surgeons. At Pancreatic Cancer 2012 in Kyoto, BRPC was also discussed at the Pancreatic Club International Joint Symposium. In this manuscript, the contents of the presented topics are briefly summarized to facilitate understanding of recent issues in managing BRPC.
机译:这份手稿总结了国际研讨会“胰腺癌2012”的一部分,该研讨会于10月4日至6日在日本京都举行,主题为“我们是团队:为胰腺癌治疗的下一步发展打开大门”。 ”边界可切除胰腺癌(BRPC)是一种特殊的临床表现,其特征介于可切除胰腺癌和局部晚期胰腺癌之间。胰腺癌的分类是一个重要的问题,因为癌症看起来可以切除,但是R1或R2切除的风险较高。考虑到切缘阴性切除术是治疗胰腺癌的基本要求,因此这一问题是胰腺外科医生最感兴趣的问题之一。在2012年京都胰腺癌大会上,在胰腺俱乐部国际联合研讨会上也讨论了BRPC。在本手稿中,简要概述了所介绍主题的内容,以帮助您理解BRPC管理中的最新问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号